Answers are grounded in this paper and cite their sources.
Hepatoblastoma is a malignant pediatric liver tumor. The currently used diagnostic serum marker for hepatoblastoma, α-fetoprotein (AFP), is not always reliable in infants with hepatoblastoma, due to the physiologically elevated levels of AFP in this age group. In this report, we show that Delta-like 1 homolog (DLK1), a protein highly expressed during fetal development, but almost completely absent after birth, and an established liver-stem cell marker, is a new candidate serum marker of hepatoblastoma, especially in young infants.
No takes yet. Share an insight, caveat, or question.
Falix et al. (2011) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: